Coeptis Pharmaceuticals in Wexford announced it is partnering with Israel-based Kitov Pharma to distribute and market a new drug in the U.S. market, according to a release.
The drug, Consensi, is intended to simultaneously treat osteoarthritis pain and hypertension.
According to the release, the agreement provides for total payments from Coeptis to Kitov of $3.5 million. In addition, Kitov will be paid 40 percent to 60 percent of Coeptis' net profit on Consensi sales. The agreement is set to last…
